GNFT Genfit S.A.

EPA · FR · Healthcare · Biotechnology · genfit.com

9.230EUR+1.43%Mkt Cap: 502.60M $P/E: —Today

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliar…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap502.60M USD

Enterprise Value568.00M USD

Revenue (TTM)65.44M USD

Gross Profit70.80M USD

Net Income (TTM)-93.44M USD

Revenue/Share1.20 EUR

Last Price9.230 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees161

CountryFR

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)97.33

PEG—

EV/EBITDA-8.64

EV/Revenue8.68

P/S7.57

P/B-9.42

EPS (TTM)-1.72

EPS (Forward)0.09

52W Range

3.40048% of range15.48

52W High15.48 EUR

52W Low3.400 EUR

Profitability

Gross Margin99.54%

Oper. Margin-34.85%

EBITDA Margin-100.47%

Profit Margin-131.38%

ROE381.47%

ROA-54.05%

Growth

Revenue Growth-30.10%

Earnings Growth—

Cash Flow & Leverage

Operating CF-28.52M USD

CapEx (TTM)3.72M USD

FCF Margin-45.54%

FCF Yield-5.93%

Net Debt71.15M USD

Net Debt/EBITDA-1.08

Balance Sheet

Debt/Equity-6.69

Current Ratio1.58

Quick Ratio1.55

Book Value/Sh-0.97 EUR

Cash/Share2.27 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)17.48 EUR

Upside (mean)+89.4%

Target Range15.00 EUR – 22.40 EUR

15.00+89.4% to mean22.40

# Analysts5

Ownership

Shares Out.50.10M

Float41.24M

Insiders13.22%

Institutions14.24%

Technical

SMA 5012.78 (-27.8%)

SMA 2009.620 (-4.1%)

Beta—

S&P 52W Chg14.58%

Avg Vol (30d)389.26K

Avg Vol (10d)645.26K

Technical Indicators

RSI (14)31.9

MACD-1.0879

MACD Signal-0.9365

MACD Hist.-0.1514

BB Upper14.32 EUR

BB Middle11.12 EUR

BB Lower7.930 EUR

BB Width57.43%

ATR (14)0.7328 EUR

Vol Ratio (20d)0.62x